Get the Stockscreener App
1,229.93
1.81%
21.81
Pre-market:
1222.94
-6.99
-0.57%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,229.93, with a volume of 3.65M.
It is up +1.81% in the last 24 hours and up +11.31% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,208.12
Open:
$1222.78
24h Volume:
3.65M
Relative Volume:
1.13
Market Cap:
$1.10T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
44.27
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+11.60%
1M Performance:
+11.31%
6M Performance:
+14.02%
1Y Performance:
+58.61%
1-Day Range:
$1,203.14
$1,238.00
1-Week Range:
$1,079.22
$1,238.00
52-Week Range:
$623.78
$1,238.00
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,229.93 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.51 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.31 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.38 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.59 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX - The Motley Fool
Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years - The Motley Fool
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug - Reuters
Lilly hands Innovent China rights to breast cancer drug Verzenios - Stock Titan
Big Pharma Has a Case of Merger Mania - The Motley Fool
Eli Lilly (LLY) Joins FDA PreCheck Pilot Program to Enhance Drug Manufacturing - GuruFocus
Eli Lilly (LLY) Joins FDA Pilot Program to Strengthen U.S. Drug Manufacturing - GuruFocus
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Eli Lilly Upgraded, Carvana Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Eli Lilly (LLY) Joins FDA PreCheck Pilot Program for Manufacturi - GuruFocus
Lilly, Regeneron selected for US program to review new manufacturing facilities faster, CNBC reports - Yahoo
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities - CNBC
How Is Eli Lilly (NYSE:LLY) Positioned As Healthcare Hits Record Highs? - Kalkine Media
Lilly partners with P2U on private Mounjaro dispensing service - Pharmacy Magazine
The Investment Case for Eli Lilly and Co (LLY): How Financial Gr - GuruFocus
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday - The Globe and Mail
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,350 - 富途牛牛
Lilly (LLY) Moves 7.1% Higher: Will This Strength Last? - Yahoo Finance
Lilly launches home delivery service for privately prescribed medicines - The Pharmacist News
ZAWYA: Lilly and Department of Health – Abu Dhabi aim to advance management of obesity and alzheimer’s disease - TradingView
Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher? - Insider Monkey
Inside Lilly's biotech startup factory - The Korea Herald
Is Eli Lilly and Company (LLY) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds? - Insider Monkey
Nesbitt to roll out weight loss drugs with support from Mounjaro maker Eli Lilly - Belfast News Letter
Eli Lilly (LLY) and BioArctic AB Enter into Research and Collaboration Agreement - Insider Monkey
Here’s What the Street Thinks About Eli Lilly and Company (LLY) - Insider Monkey
Eli Lilly Stock (LLY) Opinions on Analyst Notes Amid Obesity Drug Shifts - Quiver Quantitative
Eli Lilly & Co Soars on Drug Pipeline Breakthroughs - TipRanks
Eli Lilly (LLY) Announces Positive Phase 3 Results for Jaypirca Combination in Relapsed CLL/SLL - Insider Monkey
Why Eli Lilly Stock Jumped to a New All-Time High Today - AOL.com
Is It Too Late to Buy Eli Lilly and Co (LLY) After 7.1% Rally? G - GuruFocus
Eli Lilly and Co Options Spot-On: On June 26th, 121.72K Contracts Were Traded, With 338.92K Open Interest - 富途牛牛
ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares - Stock Titan
Form 144 ELI LILLY AND COMPANY For: 26 June By Investing.com - Investing.com Canada
Eli Lilly (LLY) Hits All-Time High Amid Healthcare Sector Rally - GuruFocus
Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms - Seeking Alpha
Eli Lilly (LLY) Gains EMA Support for Cancer and Diabetes Treatm - GuruFocus
Eli Lilly Shares Jump as Investors Focus on Medicare GLP-1 Access and Obesity Franchise Momentum - Moomoo
$Eli Lilly and Co (LLY.US)$ - Moomoo
Why is Eli Lilly stock surging today? By Investing.com - Investing.com Canada
Why is Eli Lilly stock surging today? - Investing.com
Market movers: Triller Group, Eli Lilly, Onsemi… - Proactive financial news
Eli Lilly and Co Stock (LLY) Moved Up by 6.15% on Jun 26: Drivers Behind the Movement - TradingKey
U.S. Stocks Move | Eli Lilly and Co (LLY.US) Rises Over 4% as Jaypirca Marketing Authorization Application Submitted to European Commission - Moomoo
Eli Lilly stock hits all-time high at 1183.0 USD - Investing.com
Embryo editing advances reignite ethical debates - STAT
Lilly’s Jaypirca receives positive EU regulatory opinion for CLL - Investing.com
Eli Lilly suspends access to drug discounts for some hospitals - The Republic News
LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly (LLY) Receives Positive EMA Opinion for Jaypirca Treat - GuruFocus
Flush with GLP-1 cash, Eli Lilly is on a Greater Boston shopping spree - NBC Boston
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):